Disappointing End For MolMed’s Zalmoxis Cell Therapy In EU
Real World Data Played A Key Role In The Drug’s Initial Approval
MolMed decided to the withdraw the drug's conditional marketing authorization after Phase III clinical trial results showed that the drug offered no benefit on disease-free survival.
You may also be interested in...
Coming year could feature first-time approvals in the EU for at least five gene therapies.
The European Medicines Agency explains how it used real-word evidence during recent deliberations for six products.
Is the benefit-risk profile of tafasitamab good enough for it to be recommended for EU-wide marketing approval? Codevelopers Incyte and MorphoSys may find out this week.